Comment on

• Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

  Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M; TORO 1 Study Group. Lalezari JP, et al. N Engl J Med. 2003 May 29;348(22):2175-85. doi: 10.1056/NEJMoa035026. Epub 2003 Mar 13. N Engl J Med. 2003. PMID: 12637625 Clinical Trial.
• Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

  Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M; TORO 2 Study Group. Lazzarin A, et al. N Engl J Med. 2003 May 29;348(22):2186-95. doi: 10.1056/NEJMoa035211. N Engl J Med. 2003. PMID: 12773645 Clinical Trial.
• Novel therapies based on mechanisms of HIV-1 cell entry.

  Kilby JM, Eron JJ. Kilby JM, et al. N Engl J Med. 2003 May 29;348(22):2228-38. doi: 10.1056/NEJMra022812. N Engl J Med. 2003. PMID: 12773651 Review. No abstract available.